Open Orphan article published in Drug Discovery Today

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced an article submission has been published in Drug Discovery Today, a print and online trade magazine with an emphasis on the science which underpins drug discovery and development. The published editorial is titled “Modelling the World – can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic?”

The article was written by Adrian Wildfire, Director of Scientific and Business Strategy at hVIVO, part of Open Orphan plc. Adrian is a specialist in the fields of virology, medical microbiology and parasitology.

The article explores what can be learned from using the method of human challenge trials to support vaccine development, and focuses on the role hVIVO plays in this, in particular in relation to COVID-19. hVIVO has a long history of successfully delivering human challenge studies at their state-of-the-art quarantine facility in East London.

To view the article, please follow the link: https://bit.ly/3nLct9Q

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. hVIVO welcomes volunteers under expertly supervised conditions, to further medical research, and help us to take the understanding of respiratory illnesses to a new level. Volunteers are central to the work that we do; our studies focus on testing new treatments on real people, in a safe, controlled, clinical environment.

Further details on all aspects of our volunteer programs including testimonials from previous volunteers can be found at www.flucamp.com.

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Monkeypox: The Lowdown

An ongoing outbreak of monkeypox was confirmed on 6 May 2022, beginning with a British resident who, after travelling to Nigeria, presented symptoms consistent with monkeypox on 29 April 2022. The resident returned to the United

Open Orphan Plc

Open Orphan’s hVIVO signs a £14.7m influenza contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has signed

Open Orphan Plc

How to stop the spread of germs

Flu season often wreaks havoc on workplaces, schools and communal living areas. It’s all too easy for germs to spread across surfaces and between people, swiftly infecting everyone within reach. It’s important to do what you

Open Orphan Plc

Open Orphan due diligence completed by Liberum Capital

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has today announced that further to the appointment of Liberum

Open Orphan Plc

Can elderberries help to fight the flu?

Elderberries have long been in the limelight when it comes to their health-boosting properties. In fact, Healthline declared them to be “one of the most commonly used medicinal plants in the world”. Now, researchers think they may have

Open Orphan Plc

Open Orphan to publish full year results on 7 June 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its full year results for

Open Orphan Plc

Open Orphan’s hVIVO wins a £7.3m influenza human challenge study

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has signed

Open Orphan Plc

The History of Flu

Flu & Influenza The history of the flu dates to as far as humankind. Familiar symptoms of the flu were first recorded around 400BC by Hippocrates, a Turkish seasonal winter to spring respiratory ailment that resulted

Open Orphan Plc

The lowdown on hay fever

Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can also be to dust, mould or

Open Orphan Plc

What is a Human Challenge Study?

During a human challenge study, a small number of healthy volunteers will receive a vaccine or drug which will be used to fight viruses. Volunteers are quarantined in our bespoke facilities in Whitechapel. We expose our